|
Published by: Datamonitor
Published: Feb. 11, 2005 - 203 Pages
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the psoriasis market
- Psoriasis is currently under diagnosed, but awareness is increasing with the introduction of high-profile biologic brands.
- Topical treatments such as calcipotriol and corticosteroids still dominate psoriasis treatment, leaving a gap for the moderate severity patient not effectively treated by this group, but not severe enough for an expensive or toxic systemic treatment.
- Current and pipeline biologic brands are differentiated from selected traditional brands by their perceived superior efficacy, side-effect profile, dosing frequency and ability to treat comorbidities.
- CHAPTER 2 INTRODUCTION AND SCOPE
- 2.1 Coverage of the Stakeholder Insight Survey
- Section 1 - Epidemiology
- Section 2 - Treatment patterns
- Section 3 - Key prescribing influences
- Section 4 - Treatment outcomes and patient compliance
- Section 5 - Pipeline therapies and treatment challenges
- 2.1.1 Country level ‘treatment trees’
- CHAPTER 3 COUNTRY TREATMENT TREES
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- CHAPTER 4 EPIDEMIOLOGY AND PATIENT SEGMENTATION
- 4.1 Disease definition and classification
- Plaque (vulgaris)
- Guttate
- Inverse
- Pustular
- Erythrodermic
- Diagnostic criteria
- 4.2 Epidemiology of psoriasis
- US
- Japan
- Europe
- France
- Germany
- Italy
- Spain
- UK
- 4.3 Patient segmentations
- Age
- Gender
- 4.4 Comorbidities, complications and risk factors
- Lifestyle
- Trauma
- Infections
- Other autoimmune diseases
- CHAPTER 5 DIAGNOSIS AND TREATMENT OPTIONS
- 5.1 Presentation and diagnosis
- Diagnosis rates and awareness
- Disease severity
- 5.2 Treatment rates
- 5.3 Treatment options
- Non-pharmacological
- Phototherapy
- Pharmacological
- Treatment class options
- Topical formulations
- 5.5 Off-label prescriptions
- 5.6 Treatment guidelines
- Awareness of guidelines
- Adherence to guidelines
- CHAPTER 6 PRESCRIBING TRENDS AND INFLUENCING FACTORS
- 6.1 Prescribing trends
- 6.2 Factors influencing physician decision making
- Safety vs. efficacy
- Company representative visits
- Other stakeholders
- 6.3 Brand perception
- Brand Mapping
- Awareness by physician specialty
- Biologic prescribing influences
- Biologics brand map
- Amevive
- Raptiva
- Enbrel
- Remicade
- Steroids
- Steroid prescribing influences
- Elocon
- Vitamin derivatives
- Vitamin derivative prescribing influences
- Dovonex
- Tazorac
- Soriatane
- Traditional treatments brand map
- CHAPTER 7 IMPROVING TREATMENT OUTCOMES
- 7.1 Treatment outcomes
- PASI score
- PASI: issues and debates
- Patients reaching desired outcome
- 7.2 Patient compliance
- Unmet needs
- Physician/patient education
- Patient perspective
- Cost reduction
- Therapeutic unmet needs
- 7.3 New product development
- 7.3.1 Awareness
- BG-12 (fumarate derivative)
- Avandia (rosiglitazone)
- PsorBan (topical cyclosporine)
- Oral tazarotene
- Protopic (tacrolimus)
- Elidel (pimecrolimus)
- Humira (adalimumab)
- Impact
- Pharmacist perspectives
- CHAPTER 8 OPINION LEADER AND STAKEHOLDER TRANSCRIPTS
- Dr Liz Horn, PhD - National Psoriasis Foundation
- Dr Steven Feldman, MD - Professor of Dermatology, Pathology and Public Health Sciences at the Wake Forest University School of Medicine in Winston-Salem, North Carolina
- Charles N. Ellis, MD - Professor and Associate Chair, Department of Dermatology, University of Michigan Medical, Ann Arbor, US
- Dr Michiko Haida, MD, PhD - Professor of Allergy and Immunology, Hanzoumon Hospital, Tokyo
- APPENDIX A
- Epidemiology
- Clinical trial data
- APPENDIX B
- Physician research methodology
- Brand Map Interpretation
- RX-Days 1
- Physician sample breakdown
- APPENDIX C
- THE SURVEY QUESTIONNAIRE
- Section 1: Epidemiology
- Section 2: Treatment patterns
- Section 3: Key prescribing and brand influences
- Section 4: Treatment outcomes and patient compliance
- Section 5: Pipeline therapies
- Disclaimer
AbstractIntroduction
Psoriasis is a non-life threatening but highly debilitating disease that currently has no cure. Traditional treatments often either lack efficacy or are effective but have very poor side-effect profiles, limiting them to use in severe disease only. However, the market is growing as disease awareness increases through the approval and marketing of novel biologic treatments in this indication.
Scope
- Overview of disease including detailed epidemiology, physician estimated diagnosis rates and severity split
- Breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK
- Survey of PCPs and dermatologists in the major markets to capture the treatment of the ranging severities of psoriasis, from mild to severe patients
- Review of current treatment options and clinical debate including comments from key opinion leaders
Highlights
Psoriasis is currently under diagnosed with an average of 55% of sufferers diagnosed by a physician. However, awareness of the debilitating nature of this disease is increasing, driven by the introduction of high profile biologic brands into the market.
Topical treatments such as calcipotriol and corticosteroids still dominate psoriasis treatment, leaving a gap for the moderate severity patient not effectively treated by this group, but not severe enough for an expensive or toxic systemic treatment.
Current and pipeline biologic brands are differentiated from selected traditional brands by their perceived superior efficacy, side-effect profile, dosing frequency and ability to treat comorbidities.
Reasons to Purchase
- Differentiate your product in the crowded psoriasis market through an understanding of physician perceptions of key product brands
- Identify unmet needs and the most important attributes to prescribing physicians for steroidal, biologic and vitamin derivative treatment classes
- Forecast product usage across the seven major markets based on estimated treatment class patient numbers
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
